Cost-effectiveness of docetaxel-cyclophosphamide versus doxorubicin-cyclophosphamide for breast cancer
Thompson MF, Chen L, Tangirala M, Asmar L, Jones SE
Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.
Bibliographic details
Thompson MF, Chen L, Tangirala M, Asmar L, Jones SE. Cost-effectiveness of docetaxel-cyclophosphamide versus doxorubicin-cyclophosphamide for breast cancer. American Journal of Pharmacy Benefits 2011; 3(5): 276-283